<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2681,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/98b97630ad498e6ec41205911c242621'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/98b97630ad498e6ec41205911c242621'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I537M003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I537M003">Previous Result: <span>Sheet Metal Employers Industry Promotion...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I535K003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I535K003">Next Result: <span>Teske v. CCA of Tennessee, LLC, No. 1:11...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Eli Lilly &amp; Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134 (Fed. Cir. 2012), Court Opinion'>
Eli Lilly &amp; Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I51L6003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.</div>
<div class='displayCitation'>104 U.S.P.Q.2d 1134</div>
<div class='displayCitation'>2012 BL 216158</div>
<div class='displayCitation'>689 F.3d 1368</div>
<div class='displayCitation'>bna a0d4g6h0r6</div>
<div class='displayCitation'>bna a0d4v2c6j3</div>
<div class='displayCitation'>wkffecase:26297171</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I51L6003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Eli Lilly &amp; Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Eli Lilly &amp; Co. v. Teva Parenteral Medicines, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I51L6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I51L6003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I51L6003" /><input id="title" name="title" type="hidden" value="Eli Lilly &amp; Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368, 104 U.S.P.Q.2d 1134 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="98b97630ad498e6ec41205911c242621" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I51L6003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%39%38b%39%37%36%33%30ad%34%39%38e%36ec%34%31%32%30%35%39%31%31c%32%34%32%36%32%31%2Fdocument%2FX%31I%35%31L%36%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/98b97630ad498e6ec41205911c242621/bcite/X1I51L6003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/98b97630ad498e6ec41205911c242621/bcite/X1I51L6003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/98b97630ad498e6ec41205911c242621/bcite/X1I51L6003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/98b97630ad498e6ec41205911c242621/related_content/X1I51L6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1723411398659";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">689 F.3d 1368</div>
<div class="cite" data-cite-type="ReporterOfDecisions">104 U.S.P.Q.2d 1134</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1561, 2011-1562, 2012-1037.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 216158</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
ELI LILLY AND COMPANY and Trustees of Princeton University,
Plaintiffs-Appellees, v. TEVA PARENTERAL MEDICINES, Inc. and Barr
Laboratories, Inc., Defendants-Appellants, and APP Pharmaceuticals, LLC,
Defendant-Appellant.
</center></p>
<p><center>
Eli Lilly and Company and Trustees of Princeton University,
Plaintiffs-Appellees, v. APP Pharmaceuticals, LLC, Defendant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1561, 2011-1562, 2012-1037.
</center></p>
<p><center>
August 24, 2012.
<span CLASS="page_no" data-cite="104 uspq 2d 1135" data-cite-type="ReporterOfDecisions" data-cite-pageno="1135" data-primary-citation="104 U.S.P.Q.2d 1134">[**1135]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_927273" href="#headnote_ref_pq2-dec_927273">[1]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1723411398659/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court used appropriate legal standard for evaluating obviousness-type double patenting by examining claimed subject matter as whole, rather than analyzing only differences between claims at issue, in determining whether person of ordinary skill in art would have been motivated to modify antifolate compound claimed in patentee's expired patent to create new compound with phenyl group in aryl region, claimed in patent in suit, since claims must be considered as whole, just as with obviousness analysis.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_927274" href="#headnote_ref_pq2-dec_927274">[2]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1723411398659/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Determination that patent for antifolate drug pemetrexed is not invalid for obviousness-type double patenting over antifolate compound claimed in patentee's prior patent is affirmed, since federal district court found that ways in which person of ordinary skill in art would modify prior compound would not result in pemetrexed, and this finding is owed considerable deference on appeal, since patentee's prior compound is complicated, thus providing many possibilities for modification, but district court did not find that substituting phenyl group into aryl position, as required to synthesize pemetrexed, was one among all possibilities that would have been successfully pursued, and since, therefore, there was no motivation to derive pemetrexed from earlier compound, or reason to expect success in doing so.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_927275" href="#headnote_ref_pq2-dec_927275">[3]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1723411398659/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Later patent is invalid for obviousness-type double patenting if earlier patent claims compound, disclosing utility of that compound in specification, and later patent claims method of using that compound for particular use described in specification of earlier patent; in present case, however, asserted claims for antifolate drug pemetrexed are not invalid for obviousness-type double patenting over antifolate compound claimed in patentee's prior patent, even though specification of earlier patent discloses one method for deriving pemetrexed using intermediate compound claimed therein, since asserted claims do not recite new use of earlier compound, but recite completely separate and distinct compound, since pemetrexed and prior compound are structurally different and do not embody or subsume each other, since any of several techniques that do not involve prior compound may be used to synthesize pemetrexed, and since double patenting analysis turns on evaluation of what patentee has claimed, not what it has disclosed, and foregoing exception to rule that double patenting applies to claims rather than disclosures does not apply here.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_927276" href="#headnote_ref_pq2-dec_927276">[4]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1723411398659/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Secondary considerations generally </span> <a href="http://www.bloomberglaw.com/document/1723411398659/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0907" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0907">&#9658;115.0907</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
District court erred in categorically repudiating patentee's evidence that its antifolate drug exhibited unexpected clinical properties and achieved commercial success, since such evidence may be considered in obviousness-type double patenting analysis; such error was harmless, however, since district court rejected infringement defendants' double-patenting analysis.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of Delaware,
Gregory M. Sleet, Chief Judge.
</p></div>
<span CLASS="page_no" data-cite="689 f 3d 1369" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1369" data-primary-citation="689 F.3d 1368">[*1369]</span> <div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="689 f 3d 1370" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1370" data-primary-citation="689 F.3d 1368">[*1370]</span> 
</p></div></div>
<div id="para2" printdualcolumn="true"><p>
Adam L. Perlman, Williams &amp; Connolly, LLP, of Washington, DC, argued for
plaintiff-appellee. With him on the brief were Bruce R. Genderson, Kannon K.
Shanmugam, Dov P. Grossman, and David M. Krinsky. Of counsel was Ellen E.
Ober-wetter.
</p></div>
<div id="para2" printdualcolumn="true"><p>
John C. Englander, Goodwin Procter, LLP, of Boston, MA, argued for
defendants-appellants. With him on the brief were Daryl L. Wiesen and Emily
L. Rapalino. Of counsel on the brief were Eric H. Yecies and Michael B.
Cottier.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before LOURIE, DYK, and WALLACH, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
LOURIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants Teva Parenteral Medicines, Inc., Barr Laboratories, Inc., and
APP
<span CLASS="page_no" data-cite="689 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="689 F.3d 1368">[*1371]</span> 
Pharmaceuticals, LLC appeal from the judgment of the United States District
Court for the District of Delaware holding that <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/1?citation=usp%205344932&amp;summary=yes#jcite">U.S. Patent 5,344,932</a> (the
"&prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>") is not invalid for obviousness-type double patenting. <i>See Eli</i>
<i>Lilly &amp; Co. v. Teva Parenteral Meds. Inc.</i>, No. <cite>08-335-GMS</cite>,
[<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">2011 BL 196408</a>], 2011 U.S. Dist. LEXIS 83124, <a>2011 WL 3236037</a> (D.Del. July 28, 2011). We
affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This patent infringement dispute concerns applications filed by several
generic pharmaceutical manufacturers seeking regulatory approval to market
generic formulations of the chemotherapy agent pemetrexed. To begin, we
outline the necessary background information and procedural history, as set
forth below.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Antifolate Drugs
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Folates, which include the B vitamin folic acid and its derivatives,<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
play a critical role in nucleic acid synthesis within human cells and, as
such, are required for cell growth and division. To that end, numerous
cellular enzymes recognize and process folates &mdash; some folate-specific
enzymes such as dihydrofolate reductase ("DHFR") and glycinamide
ribonucleotide formyltransferase ("GARFT") catalyze biochemical reactions
important for making both DNA and RNA, while others such as thymidylate
<span CLASS="page_no" data-cite="104 uspq 2d 1136" data-cite-type="ReporterOfDecisions" data-cite-pageno="1136" data-primary-citation="104 U.S.P.Q.2d 1134">[**1136]</span> synthetase ("TS") selectively affect DNA production.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Given the key role of folates in. DNA synthesis, and thus in cellular
replication, folate metabolism presents an attractive target for cancer
treatments because cancerous cells characteristically exhibit rapid,
unchecked division and proliferation. Accordingly, researchers and
physicians have developed numerous compounds, known as "antifolates,"
intended to inhibit one or more of the folate-specific enzymes necessary <span CLASS="page_no" data-cite="2012 bl 216158 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> for
DNA synthesis. Structurally analogous to natural folates, antifolates induce
initial recognition by one or more of the folate-specific enzymes yet
contain important structural differences that prevent the target enzyme from
carrying out its normal function. For example, the chemical structure of
folic acid is represented below &mdash; highlighting key structural features
including the bicyclic core, bridge region, aryl position, and glutamic acid
domain &mdash; along with the closely related structure of methotrexate, a
well-known antifolate that was first introduced around 1950.
<span CLASS="page_no" data-cite="104 uspq 2d 1137" data-cite-type="ReporterOfDecisions" data-cite-pageno="1137" data-primary-citation="104 U.S.P.Q.2d 1134">[**1137]</span> <span CLASS="page_no" data-cite="689 f 3d 1372" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1372" data-primary-citation="689 F.3d 1368">[*1372]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I51L6003?documentName=72546_e">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Methotrexate is used as a chemotherapy agent for treating certain cancers,
including leukemias, lymphomas, and osteosarcoma, among others. In addition
to its anti-cancer effects, however, methotrexate, like many antifolates,
exhibits significant toxicity due to deleterious effects on non-cancerous,
healthy cells. Such toxicity is thought to arise at least in part because
methotrexate primarily inhibits DHFR and therefore substantially impairs DNA
<i>and</i> RNA synthesis. While DNA synthesis is of principal importance for
actively dividing cells (<i>e.g.</i>, cancer cells), ongoing RNA syn-thesis is
necessary for essentially all living cells in the body. Methotrexate and
other antifolate drugs that inhibit both the DNA and RNA synthesis pathways
are thus prone to undesirable off-target effects.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the 1980s, researchers sought to develop antifolates capable of
inhibiting TS, which would selectively impede DNA synthesis and presumably
mitigate the toxicity issues associated with methotrexate and other
then-existing antifolates. One such effort led by Prof. Edward Taylor, a
chemist at Princeton University, yielded pemetrexed, the antifolate at the
heart of this appeal:
<span CLASS="page_no" data-cite="689 f 3d 1373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1373" data-primary-citation="689 F.3d 1368">[*1373]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I51L6003?documentName=72546_f">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As with methotrexate, pemetrexed exhibits some structural similarity to
folic acid. One key difference that distinguishes pemetrexed from folic acid
and methotrexate is that pemetrexed contains a pyrrolo[2,3-d]pyrimidine
bicyclic core, characterized by a five-member ring fused with a six-member
ring, rather than the dual six-member rings found in the pteridine cores of
folic acid and methotrexate. After synthesizing pemetrexed, the Princeton
group collaborated with researchers at Eli Lilly to test the new compound
for antifolate activity, and the results soon revealed that pemetrexed acts
as a potent inhibitor of TS. Princeton and Eli Lilly (together, "Lilly")
thereafter began exploring for related compounds with similar activity as TS
inhibitors and pursuing preclinical and clinical studies to evaluate
promising candidates for therapeutic use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Among the many pemetrexed-related compounds that were developed and
tested, pemetrexed itself proved to be the best therapeutic candidate and
ultimately won FDA approval in 2004 for use in treating mesothelioma and
then in 2008 for treatment of non-small cell lung cancer. Lilly manufactures
and distributes pemetrexed under the brand name Alimta&reg;.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Lilly's Patents
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In conjunction with their <span CLASS="page_no" data-cite="2012 bl 216158 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> antifolate research, the inventors filed U.S.
<cite>patent application 07/448,742</cite> (the "&prime;<cite>742 application</cite>") on December 11, 1989.
The &prime;<cite>742 application</cite> disclosed and claimed pemetrexed as well as a <span CLASS="page_no" data-cite="104 uspq 2d 1138" data-cite-type="ReporterOfDecisions" data-cite-pageno="1138" data-primary-citation="104 U.S.P.Q.2d 1134">[**1138]</span> broader
group of related antifolates containing pemetrexed's characteristic core
structure. The &prime;<cite>742 application</cite>, though itself eventually abandoned, founded
a family of related applications that ultimately yielded the three patents
at issue in this appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> issued on September 6, 1994, from an application filed on
March 22, 1991, claiming priority from the &prime;<cite>742 application</cite> through a series
of continuations. Claim 3 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> claims pemetrexed. Claims 1, 2,
and 7 are generic, Markush-style claims that encompass pemetrexed as well as
other structurally related antifolates.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/1?citation=usp%205028608&amp;summary=yes#jcite">U.S. Patent 5,028,608</a> (the "&prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a>") issued on July 2, 1991, from an
application filed on May 24, 1990, as a continuation-in-part of the &prime;<cite>742
application</cite>. The &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a> claims, <i>inter alia</i>, an antifolate (the "&prime;608
Compound") that differs from pemetrexed only in its aryl region &mdash; the 608
Compound
<span CLASS="page_no" data-cite="689 f 3d 1374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1374" data-primary-citation="689 F.3d 1368">[*1374]</span> 
contains a five-member thiophene ring in place of pemetrexed's six-member
benzene ring.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I51L6003?documentName=72546_g">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/1?citation=usp%205248775&amp;summary=yes#jcite">U.S. Patent 5,248,775</a> (the "&prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>") issued on September 28, 1993,
from an application filed January 31, 1992, as a continuation-in-part of the
application that led to the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>. The &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a> discloses a family
of chemical intermediates that can be used to make a variety of antifolates,
including pemetrexed, that contain a pyrrolo[2,3-d]pyrimidine bicyclic core.
Among others, the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a> claims a compound (the "&prime;775 Intermediate")
that is used as an intermediate in one method for making pemetrexed. The
&prime;775 Intermediate differs from pemetrexed in having a carbon-carbon triple
bond in its bridge region and three protecting groups at substituent
positions in its core and glutamate domains.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> In addition, Examples 6
and 10 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a> disclose reduction and hydrolysis reactions,
respectively, that could together be used to derive pemetrexed from the &prime;775
Intermediate. &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a> col. 9, 1. 59 &mdash; col. 10, 1. 5; col. 12, 11. 51-66.
<span CLASS="page_no" data-cite="104 uspq 2d 1139" data-cite-type="ReporterOfDecisions" data-cite-pageno="1139" data-primary-citation="104 U.S.P.Q.2d 1134">[**1139]</span> <span CLASS="page_no" data-cite="689 f 3d 1375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1375" data-primary-citation="689 F.3d 1368">[*1375]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1I51L6003?documentName=72546_h">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<cite>932</cite>, &prime;<cite>608</cite>, and &prime;<cite>775 patents</cite> were assigned to the Trustees of
Princeton University and exclusively licensed to Eli Lilly. The &prime;<cite>608</cite> and
&prime;<cite>775 patents</cite> have expired, but the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> remains in effect until July
24, 2016, due to a patent term extension of over four years to compensate
for delays in the regulatory approval of Alimta&reg;. <i>See</i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEJ01M003?jcsearch=35%20usc%20156&amp;summary=yes#jcite">35 U.S.C. &sect; 156</a>. Lilly
holds a further six months of market exclusivity over pemetrexed pursuant to
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEI5OS003?jcsearch=21%20usc%20355a&amp;summary=yes#jcite">21 U.S.C. &sect; 355a</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. District Court Proceedings
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Teva Parenteral Medicines, Inc., Barr Laboratories, Inc., and APP
Pharmaceuticals, LLC (collectively, "Teva") filed abbreviated new drug
applications ("ANDAs") seeking approval to manufacture and sell generic
versions of Alimta&reg; before the expiration of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>. Those ANDAs
each included a Paragraph IV certification asserting that the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>
was invalid, unenforceable, or would not be infringed by the proposed
generic products. <i>See</i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii)(IV). In response, Lilly
brought suit in the United States District Court for the <span CLASS="page_no" data-cite="2012 bl 216158 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> District of
Delaware, alleging infringement of claims 1, 2, 3, and 7 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>
pursuant to <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During the proceedings, Teva conceded infringement but maintained that the
asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> were invalid for obviousness-type double
patenting over two earlier-issued claims: (1) claim 3 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a>,
which claims the &prime;608 Compound, and (2) claim 7 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>, which
claims the &prime;775 Intermediate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Regarding the &prime;608 Compound, Teva presented evidence that various
antifolates known at the time of the invention contained a phenyl group in
the aryl position, and Teva contended that it would have been obvious to
incorporate a phenyl group into the &prime;608 Compound consistent with such
"conventional wisdom" in the field. As to the &prime;775 Intermediate, Teva argued
that the asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> constitute a use for the &prime;775
Intermediate &mdash; <i>i.e.</i>, synthesizing pemetrexed &mdash; that had already been
disclosed in the specification of the earlier-issued &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>, rendering
such claims invalid for obviousness-type double patenting. In addition, Teva
argued that even ignoring the specification of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>, an
ordinarily skilled chemist presented with the &prime;775 Intermediate immediately
would have recognized pemetrexed as an obvious potential end product.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following a bench trial, the district court rejected Teva's arguments and
held that claims 1, 2, 3, and 7 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>
<span CLASS="page_no" data-cite="689 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="689 F.3d 1368">[*1376]</span> 
were not invalid for obviousness-type double patenting over either the &prime;608
Compound or the &prime;775 Intermediate. <i>Eli Lilly</i>, [<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">2011 BL 196408</a>], 2011 WL 3236037, at *2-4.
Specifically, the district court rejected Teva's "focus[] only on the aryl
region of the [&prime;608 Compound] in isolation," finding persuasive other
evidence indicating that one of skill in the art would have pursued changes
outside of the aryl region to improve TS inhibition and would have avoided
introducing a phenyl group into the &prime;608 Compound based on previous reports
of toxicity with analogous antifolate structures. <i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">Id</a>.</i> at *4. The district
<span CLASS="page_no" data-cite="104 uspq 2d 1140" data-cite-type="ReporterOfDecisions" data-cite-pageno="1140" data-primary-citation="104 U.S.P.Q.2d 1134">[**1140]</span> court also declined to hold the asserted claims invalid over the &prime;775
Intermediate. The court held (1) that the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> "does not claim the
use of the [&prime;775 Intermediate]," so the teachings from the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>'s
specification were inapplicable to its obviousness-type double patenting
analysis, and (2) that pemetrexed would not have been obvious from the
structure of the &prime;775 Intermediate because, among many possible choices, a
person of ordinary skill would not have made the structural changes
necessary to derive pemetrexed. <i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">Id</a>.</i> at *2-3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the district court entered a final judgment in Lilly's favor
and enjoined approval of Teva's proposed generic pemetrexed products until
after the expiration of Lilly's exclusive rights on January 24, 2017. <i>Eli</i>
<i>Lilly &amp; Co. v. Teva Parenteral Meds. Inc.</i>, Nos. <cite>08-335-GMS</cite>, <cite>08-384-GMS</cite>,
<cite>08-860-GMS</cite>, and <cite>09-272-GMS</cite> (D.Del. Aug. 22, 2011) (Am. Final J. Order), ECF
No. 115. Teva timely appealed, and we have jurisdiction under
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The sole disputed issue in this appeal is whether the asserted claims of
the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> are invalid for obviousness-<span CLASS="page_no" data-cite="2012 bl 216158 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> type double patenting. The
doctrine of obviousness-type double patenting is intended to "prevent the
extension of the term of a patent . . . by prohibiting the issuance of the
claims in a second patent not patentably distinct from the claims of the
first patent." <i>In re Longi</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">759 F.2d 887</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">892</a> (Fed.Cir.1985). "A later
patent claim is not patentably distinct from an earlier claim if the later
claim is obvious over, or anticipated by, the earlier claim." <i>Eli Lilly &amp;</i>
<i>Co. v. Barr Labs., Inc.</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">251 F.3d 955</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X50SKQ?jcsearch=251%20f%203d%20955&amp;summary=yes#jcite">968</a> (Fed.Cir.2001). As with statutory
obviousness under <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>, obviousness-type double patenting is an
issue of law premised on underlying factual inquiries. <i>Otsuka Pharm. Co. v.</i>
<i>Sandoz, Inc.</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HMJKG003?jcsearch=678%20f%203d%201280&amp;summary=yes#jcite">678 F.3d 1280</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HMJKG003?jcsearch=678%20f%203d%201280&amp;summary=yes#jcite">1290</a> (Fed. Cir.2012). Accordingly, we consider
the district court's ultimate conclusion on obviousness-type double
patenting without deference, but we review any predicate findings of fact
for clear error. <i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HMJKG003?jcsearch=678%20F.3d%201280&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. The &prime;608 Compound
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We first address the &prime;608 Compound. Claim 3 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a> recites the
&prime;608 Compound,
<span CLASS="page_no" data-cite="689 f 3d 1377" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1377" data-primary-citation="689 F.3d 1368">[*1377]</span> 
an antifolate that is structurally related to pemetrexed but never advanced
to clinical use. As described, the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a> issued in July 1991, more
than three years before the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> issued with its claims covering
pemetrexed. The question, then, is whether the asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932
patent</a> are patentably distinct from Lilly's earlier-issued claim to the &prime;608
Compound.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_927273" href="#headnote_pq2-dec_927273">[1]</a> On appeal, Teva contends that the district court erred by failing to
invalidate the claims for obviousness-type double patenting. Teva's primary
argument concerns the appropriate legal standard for evaluating
obviousness-type double patenting. Relying on our decision in <i>Amgen Inc. v.</i>
<i>Hoffman-La Roche Ltd.</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1BN634003?jcsearch=580%20f%203d%201340&amp;summary=yes#jcite">580 F.3d 1340</a> (Fed.Cir.2009), Teva contends that the
correct analysis involves only the <i>differences</i> between the claims at issue,
so that any features held in common between the claims &mdash; in this case, all
but the aryl regions of the &prime;608 Compound and pemetrexed &mdash; would be excluded
from consideration. In <i>Amgen</i>, we explained that once the differences between
claims are established, the obviousness-type double patenting analysis
entails determining "whether the differences in subject matter between the
claims render the claims patentably distinct." <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1BN634003?jcsearch=580%20F.3d%201340&amp;summary=yes#jcite">580 F.3d at 1361</a>. But those
differences cannot be considered in isolation &mdash; the claims must be
considered as a whole. <i>Amgen</i> expressly noted that "[t]his part of the
obviousness-type double patenting analysis is analogous to an obviousness
analysis under <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>." <i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1BN634003?jcsearch=580%20F.3d%201340&amp;summary=yes#jcite">Id</a>.</i> And just as <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">&sect; 103(a)</a> requires asking
whether the claimed subject matter "as a whole" would have been obvious to
one of skill in the art, so too must the subject matter of the &prime;932 claims
be considered "as a whole" to determine whether the &prime;608 Compound <span CLASS="page_no" data-cite="104 uspq 2d 1141" data-cite-type="ReporterOfDecisions" data-cite-pageno="1141" data-primary-citation="104 U.S.P.Q.2d 1134">[**1141]</span> would have
made those claims obvious for purposes of obviousness-type double patenting.
<i>Gen. Foods Corp. v. Studiengesellschaft Kohle mbH</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X3ACET?jcsearch=972%20f%202d%201272&amp;summary=yes#jcite">972 F.2d 1272</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X3ACET?jcsearch=972%20f%202d%201272&amp;summary=yes#jcite">1278</a>
(Fed.Cir.1992) ("Claims must be read as a whole in analyzing a claim of
double patenting."). Thus, the district court did not err by examining
whether one of ordinary skill in the art would have been motivated to modify
the &prime;608 Compound to create pemetrexed, considering the compounds as <span CLASS="page_no" data-cite="2012 bl 216158 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> a
whole.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the merits, Teva also disputes the district court's findings and
conclusions in view of the evidence presented. Specifically, Teva contends
(1) that placing a phenyl group in the aryl position represented inescapable
"conventional wisdom" in the field based on antifolate structures known at
the time, (2) that the district court erred in finding that one of skill in
the art would have considered a phenyl group undesirable within the
structural context of the &prime;608 Compound, and (3) that the district court
erred by discounting its theory that principles of bioisosterism<a HREF="#fn600" name="fnref_fn600">[fn6]</a> would
have suggested replacing the &prime;608 Compound's thienyl with phenyl.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lilly defends the district court's findings, arguing that the evidence
amply supported the court's view that a person of ordinary skill would not
have had reason to manipulate the &prime;608 Compound to produce pemetrexed. Lilly
contended, and the district court found, that a chemist at the time seeking
to develop TS inhibitors would have looked specifically to data from that
emerging sub-discipline rather
<span CLASS="page_no" data-cite="689 f 3d 1378" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1378" data-primary-citation="689 F.3d 1368">[*1378]</span> 
than attempting to emulate the "conventional" antifolates highlighted by
Teva. In fact, according to Lilly, the contemporary experience and
understanding in the TS field not only would have failed to suggest
substituting a phenyl group into the &prime;608 Compound, but earlier reports of
associated inefficacy and toxicity would have actively dissuaded one from
doing so. Finally, Lilly maintains that bioisosterism provides no basis for
predicting whether a substituted compound will prove more or less effective
than the original.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_927274" href="#headnote_pq2-dec_927274">[2]</a> Based on the evidence presented at trial, we discern no error in the
district court's findings or its conclusion that the asserted claims are
patentably distinct from the &prime;608 Compound. In the chemical context, we have
held that an analysis of obviousness-type double patenting "requires
identifying some reason that would have led a chemist to modify the earlier
compound to make the later compound with a reasonable expectation of
success." <i>Otsuka</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HMJKG003?jcsearch=678%20F.3d%201280&amp;summary=yes#jcite">678 F.3d at 1297</a>. Here, the district court considered the
parties' arguments and evidence, particularly their conflicting expert
testimony as to how an ordinarily skilled chemist presented with the &prime;608
Compound would have been motivated to proceed at the time. In its decision,
the court credited Lilly's evidence to find that "the ways in which a person
of ordinary skill in the art would modify [the &prime;608 Compound] would not
result in pemetrexed." <i>Eli Lilly</i>, [<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">2011 BL 196408</a>], 2011 WL 3236037, at *4. We owe that
finding considerable deference on appeal, and we see no clear error based on
the record before us. Moreover, a complicated compound such as the &prime;608
Compound provides many opportunities for modification, but the district
court did not find that substituting a phenyl group into the aryl position
was the one, among all the possibilities, that would have been successfully
pursued. Thus, absent any motivation to derive pemetrexed from the &prime;608
Compound or reason to expect success in doing so, the district court
correctly concluded <span CLASS="page_no" data-cite="2012 bl 216158 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> that the asserted claims were not invalid for
obviousness-type double patenting over the &prime;608 Compound.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. The &prime;775 Intermediate
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As with the &prime;608 Compound, Lilly's claim covering the &prime;775 Intermediate
was issued before the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a>. As an independent basis for holding the
&prime;932 claims invalid for obviousness-type double patenting, Teva similarly
contends that pemetrexed is not patentably distinct from the &prime;775
Intermediate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Teva's arguments regarding the &prime;775 Intermediate can be summarized as
follows. According to Teva, the &prime;775 Intermediate is used to make
pemetrexed, and Lilly disclosed that use in the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>. By later
claiming pemetrexed itself, Teva maintains, the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> appropriates a
previously disclosed use for a previously patented compound, which renders
the asserted &prime;932 claims invalid for obviousness-type double patenting under
a line of our precedent including <i>In re Byck</i>, 18 CCPA 1208, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20f%202d%20665&amp;summary=yes#jcite">48 F.2d 665</a>
(1931), and <i>Sun Pharmaceutical Industries, Ltd. v. Eli Lilly &amp; Co.<span CLASS="page_no" data-cite="104 uspq 2d 1142" data-cite-type="ReporterOfDecisions" data-cite-pageno="1142" data-primary-citation="104 U.S.P.Q.2d 1134">[**1142]</span> </i>,
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1DNRP2003?jcsearch=611%20f%203d%201381&amp;summary=yes#jcite">611 F.3d 1381</a> (Fed.Cir.2010). We conclude that Teva's reliance on <i>Byck, Sun</i>,
and related cases is unsound and that the district court did not err when it
up-held the asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> over the &prime;775 Intermediate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As a general rule, obviousness-type double patenting determinations turn
on a comparison between a patentee's earlier and later claims, with the
earlier patent's
<span CLASS="page_no" data-cite="689 f 3d 1379" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1379" data-primary-citation="689 F.3d 1368">[*1379]</span> 
written description considered only to the extent necessary to construe its
claims. <i>E.g., In re Avery</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XIH79N?jcsearch=518%20f%202d%201228&amp;summary=yes#jcite">518 F.2d 1228</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XIH79N?jcsearch=518%20f%202d%201228&amp;summary=yes#jcite">1232</a> (CCPA 1975). This is so
because the non-claim portion of the earlier patent ordinarily does not
qualify as prior art against the patentee and because obviousness-type
double patenting is concerned with the improper extension of exclusive
rights &mdash; rights conferred and defined by the <i>claims.</i> The focus of the
obviousness-type double patenting doctrine thus rests on preventing a
patentee from claiming an obvious variant of what it has previously <i>claimed</i>,
not what it has previously <i>disclosed. See generally Gen. Foods</i>,
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X3ACET?jcsearch=972%20f%202d%201272&amp;summary=yes#jcite">972 F.2d at 1280-32</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The cases on which Teva relies represent a limited exception to this
customary framework. In <i>Byck</i>, our predecessor court considered
obviousness-type double patenting rejections against claims to an insulated
coil made up of a conductive winding material coated with an "infusible,
flexible, phenol-fatty oil composition." <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">48 F.2d at 665</a>. The patent
applicant, Byck, had earlier obtained a patent claiming the same phenol-oil
composition, and-the prior art disclosed similar coils coated with other
insulating compositions. <i></i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">Id. at 665-66</a>. Moreover, Byck's earlier patent had
discussed using his phenol-oil composition to produce adherent insulating
films on metal substrates. <i></i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">Id. at 666</a>. The court concluded that, in view of
the prior art and Byck's earlier patent, the pending claims were drawn not
to a second, distinct invention "but only . . . an obvious use of the
composition there patented." <i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">Id</a>.</i> The court explained:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      It would shock one's sense of justice if an inventor could receive
    a patent upon a composition of matter, setting out at length in the
    specification the useful purposes of such composition, manufacture
    <span CLASS="page_no" data-cite="2012 bl 216158 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> and sell it to the public, and then prevent the public from making
    any beneficial use of such product by securing patents upon each of
    the uses to which it may be adapted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">Id</a>.</i> Thus, even though Byck's earlier patent was not prior art, the court
held that its disclosure of an intended use for the previously claimed
phenol-oil composition could be used in the obviousness-type double
patenting analysis to reject a later claim directed to that use of the same
compound. <i></i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">Id. at 667</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A trio of our more recent decisions applied the same exception to allow
limited consideration of teachings in an earlier-issued patent's
specification. In <i>Geneva Pharmaceuticals, Inc. v. GlaxoSmithKline PLC</i>,
<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XF7HAM?jcsearch=349%20f%203d%201373&amp;summary=yes#jcite">349 F.3d 1373</a> (Fed.Cir.2003), the plaintiff had patented methods of using
clavulanic acid to mitigate antibiotic resistance when treating bacterial
infections. The plaintiff then acquired a preexisting patent that claimed
clavulanic acid compositions and disclosed their utility for treating
patients harboring antibiotic-resistant bacteria. <i></i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XF7HAM?jcsearch=349%20F.3d%201373&amp;summary=yes#jcite">Id. at 1377</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XF7HAM?jcsearch=1385&amp;summary=yes#jcite">1385</a>. In that
case, we relied on <i>Byck</i> to hold the plaintiffs method claims invalid for
double patenting: "Our predecessor court recognized that a claim to a method
of using a composition is not patentably distinct from an earlier claim to
the identical composition in a patent disclosing the identical use." <i>Id.</i> at
1385-36 (citing, <i>Byck</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X222FF?jcsearch=48%20F.2d%20665&amp;summary=yes#jcite">48 F.2d at 666</a>). Similarly, in <i>Pfizer, Inc. v. Teva</i>
<i>Pharmaceuticals USA Inc.</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X18JV7I003?jcsearch=518%20f%203d%201353&amp;summary=yes#jcite">518 F.3d 1353</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X18JV7I003?jcsearch=518%20f%203d%201353&amp;summary=yes#jcite">1363</a> (Fed.Cir.2008), we held claims
to methods of administering a particular anti-inflammatory drug invalid for
obviousness-type double patenting where the patentee's earlier patent
claimed the drug itself and disclosed the same methods of administering
<span CLASS="page_no" data-cite="689 f 3d 1380" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1380" data-primary-citation="689 F.3d 1368">[*1380]</span> 
the drug. And in <i>Sun</i>, the patent holder had developed an antiviral compound,
gemcitabine, that also proved useful for treating cancer. An initial patent
issued with composition claims covering gemcitabine as well as method claims
drawn to using the drug to treat herpesvirus infections; also mentioned in
the specification, but not claimed, was gemcitabine's potential anticancer
activity. <i>Sun</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1DNRP2003?jcsearch=611%20F.3d%201381&amp;summary=yes#jcite">611 F.3d at 1383</a>. As in <i>Geneva</i> and <i>Pfizer</i>, we held the
patentee's subsequent claims to methods of using gemcitabine to treat cancer
invalid for double patenting, looking to the disclosure of anticancer
utility in the first patent's specification. <i></i><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1DNRP2003?jcsearch=611%20F.3d%201381&amp;summary=yes#jcite">Id. at 1386-89</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Byck, Geneva, Pfizer</i>, and <i>Sun</i> thus "address the situation in which an
earlier patent claims a compound, disclosing the utility of that compound in
the specification, and a later <span CLASS="page_no" data-cite="104 uspq 2d 1143" data-cite-type="ReporterOfDecisions" data-cite-pageno="1143" data-primary-citation="104 U.S.P.Q.2d 1134">[**1143]</span> patent claims a method of using that compound
for a particular use described in the specification of the earlier patent."
<i>Sun</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1DNRP2003?jcsearch=611%20F.3d%201381&amp;summary=yes#jcite">611 F.3d at 1389</a>. Furthermore, in each of those cases, the claims held
to be patentably indistinct had in common the same compound or composition &mdash;
that is, each subsequently patented "use" constituted a, or the, disclosed
use for the previously claimed substance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_927275" href="#headnote_pq2-dec_927275">[3]</a> That is not the case before us. Rather than a composition and a previously
disclosed use, the claims at issue recite two separate and distinct chemical
compounds: the &prime;775 Intermediate and pemetrexed, <span CLASS="page_no" data-cite="2012 bl 216158 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> differing from each other
in four respects. That alone suffices to undermine Teva's argument regarding
the &prime;775 Intermediate, for the asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932 patent</a> do not
recite a <i>use</i> of the <i>same compound</i>, but a <i>different compound</i> altogether. The
cited cases therefore do not govern.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, even if one composition could somehow be considered a "use"
of another, the record makes clear that, unlike in the cited cases, Lilly's
successive claims are wholly independent of one another. For example,
pemetrexed and the &prime;775 Intermediate exhibit substantial structural
differences, and neither embodies or subsumes the other. Moreover,
pemetrexed can be made via any of several synthetic techniques, many of
which do not involve the &prime;775 Intermediate. The &prime;775 Intermediate and
pemetrexed are thus separate and independent chemical compounds; Lilly's
original claim to the &prime;775 Intermediate offered no protection for
pemetrexed, and its claims to pemetrexed do not incorporate or require use
of the &prime;775 Intermediate. The particular concerns motivating our prior
decisions are thus absent here. In sum, although the specification of the
&prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a> discloses one method for deriving pemetrexed using the &prime;775
Intermediate, we agree with the district court's conclusion that that
disclosure does not render Lilly's claims to pemetrexed invalid for
obviousness-type double patenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the district court recognized, the correct double patenting analysis in
this case turns on an evaluation of what Lilly has claimed, not what it has
disclosed. Putting aside the teachings in the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>'s specification,
Teva's double patenting contentions evaporate. The evidence of record
characterizes the &prime;775 Intermediate as a versatile compound from which a
skilled chemist could derive innumerable final products beyond just
pemetrexed, and the district court found that there would have been "no
reason" to pursue pemetrexed among the various other avenues that would have
been considered possible at the time. We see no error in the district
court's findings or its conclusion on this point, and, although not
controlling, we further note that its analysis comports
<span CLASS="page_no" data-cite="689 f 3d 1381" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1381" data-primary-citation="689 F.3d 1368">[*1381]</span> 
with PTO guidelines on the patentability of related products. <i>See</i> Manual of
Patent Examining Procedure <cite>&sect; 806.05(j)</cite> (8th ed., rev. 8, 2010) ("[A]n
intermediate product and a final product can be shown to be distinct
inventions if the intermediate and final products are mutually exclusive
inventions (not overlapping in scope) that are not obvious variants, and the
intermediate product as claimed is useful to make other than the final
product as claimed."). In sum, the district court correctly concluded that
the asserted claims are not invalid for obviousness-type double patenting
over the &prime;775 Intermediate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. Objective Indicia of Nonobviousness
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_927276" href="#headnote_pq2-dec_927276">[4]</a> Finally, Lilly presented evidence at trial that pemetrexed exhibited
unexpected clinical properties and achieved considerable commercial success.
But the district court disregarded that evidence, holding that "secondary
considerations <span CLASS="page_no" data-cite="2012 bl 216158 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> are not relevant to the analysis of invalidity for
obviousness-type double patenting." <i>Eli Lilly</i>, [<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1FUN4E003?jcsearch=2011%20BL%20196408&amp;summary=yes#jcite">2011 BL 196408</a>], 2011 WL 3236037, at *1 n. 1.
For that proposition, the district court relied on a footnote in <i>Geneva</i>, in
which we remarked only that inquiry into secondary considerations is not
required in every obviousness-type double patenting analysis, not that such
evidence is off-limits or irrelevant. <i>See Geneva</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/XF7HAM?jcsearch=349%20F.3d%201373&amp;summary=yes#jcite">349 F.3d at 1378</a> n. 1."
The district court's categorical repudiation of Lilly's evidence was
therefore erroneous. When offered, such evidence should be considered; a
fact-finder "must withhold judgment on an obviousness challenge until it has
considered all relevant evidence, including that relating to the objective
considerations." <i>In re Cyclobenzaprine Hydrochloride Extended-Release</i>
<i>Capsule Patent Litig.</i>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HF6KC003?jcsearch=676%20f%203d%201063&amp;summary=yes#jcite">676 F.3d 1063</a>, <a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1HF6KC003?jcsearch=676%20f%203d%201063&amp;summary=yes#jcite">1079</a> (Fed.Cir.2012). Given that the
district court nonetheless rejected Teva's double patenting arguments,
however, such error was, in this instance, harmless.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In view of the foregoing, we hold that the asserted claims of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GOG891GGJ?jcsearch=usp%205344932&amp;summary=yes#jcite">932
patent</a> are not invalid <span CLASS="page_no" data-cite="104 uspq 2d 1144" data-cite-type="ReporterOfDecisions" data-cite-pageno="1144" data-primary-citation="104 U.S.P.Q.2d 1134">[**1144]</span> for obviousness-type double patenting over claim 3 of
the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2G08G6020J?jcsearch=usp%205028608&amp;summary=yes#jcite">608 patent</a> or claim 7 of the &prime;<a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X2GGGG73H8J?jcsearch=usp%205248775&amp;summary=yes#jcite">775 patent</a>. We have considered each of
Teva's remaining arguments and find them unpersuasive. Accordingly, the
judgment of the district court is
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Although folic acid itself predominates in most dietary supplements
and fortified foods, the compound naturally occurs in various other chemical
forms including folic acid salts and esters. For convenience, we refer to
folic acid and such related compounds collectively as "folates."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Purines and pyrimidines are key building blocks in the production of
both RNA and DNA. DHFR and GARFT participate in global purine synthesis, so
those enzymes affect both DNA and RNA production. In contrast, TS serves
only in the production of deoxythymidine monophosphate, a pyrimidine
nucleotide that is incorporated into DNA but not RNA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The parties use the, expressions "thienyl group" and "phenyl group";
accordingly, we will also.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Protecting groups are selectively reversible chemical modifications
often used to prevent unwanted side reactions during multistep organic
syntheses. In general, protecting groups are introduced at one or more
particularly reactive positions in a complex molecule to stabilize or
"protect" those parts of the molecule during later chemical manipulation of
other target sites. Once a desired modification has been achieved elsewhere
in the molecule, the protecting groups can be removed to reconstitute a
reactive substituent at each protected position. The &prime;775 Intermediate
contains a pivaloyl protecting group (denoted "t-BuCO") in its core region
and two methyl ester protecting groups (denoted "OMe") in its glutamate
domain:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> After trial, individual appellant APP Pharmaceuticals supplemented its
ANDA to add a further Paragraph IV certification relating to a particular
pemetrexed dosage form. Appellees initiated a new infringement suit to
address APP's supplemental ANDA filing, and the parties agreed to be bound
in that action by any judgment in the antecedent litigation. Accordingly,
following its August 22, 2011, judgment in favor of Lilly, the district
court entered a stipulated judgment against APP as to its supplemental ANDA
filing. <i>Eli Lilly &amp; Co. v. APP Pharm., LLC</i>, No. <cite>11-628-GMS</cite> (D.Del. Oct. 17,
2011) (Stipulation and J. Order), ECF No. 10. We granted APP's unopposed
motion to consolidate that action with the related matters on appeal. <i>Eli</i>
<i>Lilly &amp; Co. v. Teva Parenteral Meds. Inc.</i>, Nos. <cite>2011 &mdash; 1561</cite>, <cite>1562</cite>, <cite>2012-1037</cite>
(Fed.Cir. Nov. 29, 2011) (Order Consolidating Appeals).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> Bioisosterism refers to a process that involves replacing one atom or
functional group in a molecule with another of similar chemical, physical,
or electronic properties in hopes that the substitution will result in
similar or enhanced activity.
</p></div>
<!--BBLS DD 1723411398659-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I51L6003/history">Direct History (3)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I51L6003/analysis">Case Analysis (5)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I51L6003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
5
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1Q6M0UQR8O2">11-01561 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1Q6M0UQRG82">11-01562 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/98b97630ad498e6ec41205911c242621/document/X1Q6M23GQS82">12-01037 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/98b97630ad498e6ec41205911c242621/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "98b97630ad498e6ec41205911c242621";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY181021&previousPageId=&previousActivityInstanceId=ENTITY796f2b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:15:54-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I51L6003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY796f2b&previousPageId=&previousActivityInstanceId=ENTITY7ceb60&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:15:52-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I51L6003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I51L6003";
$('#page_loader').show().spin();
JUDGE_IDS=["1718421","3408847","4141613"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
